Drug intelligence / Profile preview

EVX-03

Development stage
Discontinued
Lead developer
Evaxion
Modality
Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Parenteral
01

Overview

EVX-03 is a DNA-based personalized neoantigen cancer vaccine developed by Evaxion Biotech. It is designed as an immunotherapy for the treatment of advanced solid tumors, with a primary focus on non-small cell lung cancer (NSCLC). The vaccine utilizes Evaxion’s AI-driven platform to identify patient-specific tumor neoantigens and endogenous retrovirus (ERV) fragments. These are encoded into a plasmid construct that also includes a genetic immune adjuvant and an antigen-presenting cell (APC)-targeting unit to enhance immune response. Preclinical studies have shown significant tumor reduction at low doses and robust immunogenicity. As of late 2024, EVX-03 remains in preclinical development with plans for clinical trials targeting NSCLC[1][4][5][6][8].

Other names
EVX-03EVX03EVX 03

Beyond the preview

Go deeper on EVX-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVX-03.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call